Interview 26 May 2021 Immuno-Oncology: From Science Fiction to the Mainstream In just a couple of decades, immuno-oncology has taken center stage in the biotechnology industry. We discuss the evolution of the field with experts who have been in it from the very beginning. While immuno-oncology is one of the hottest areas of medicine at the moment, that wasn’t the case 20 years ago. The idea […] May 26, 2021 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Dec 2020 A Year to Remember: The Biggest European Biotech News in 2020 The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […] December 28, 2020 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Aug 2020 Why are Some European Biotechs Going Public Without an IPO? European biotech companies are flocking to the Nasdaq Stock Market in 2020, but not all are going the traditional Initial Public Offering (IPO) route. What does this mean for the dominance of the biotech IPO in Europe? In spite of the Covid-19 pandemic, biotech IPOs have continued unabated. In fact, a report from Bioworld found […] August 13, 2020 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Feb 2020 Immatics Partners GSK in Deal Worth €1B to Develop Cancer Therapies The German biotech Immatics will partner with GSK and could receive more than €1B from the big pharma for developing cancer immunotherapies based on engineered immune T-cells. Immatics will collaborate with GSK to develop two T-cell therapies that express a protein engineered to detect cancer antigens and kill cancer cells. In return, Immatics will receive […] February 20, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 7 Sep 2019 Why Being in a New Field From the Start Can Pay Off in the Long Run The field of immuno-oncology has expanded out of all recognition over the last few years. Having co-founded one of the first cancer immunotherapy biotechs — Immatics — CEO Harpreet Singh has seen it all happen. He plans to take advantage of the company’s head start to tackle solid tumors with its T-cell redirecting therapies. Singh […] September 7, 2019 - 12 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2019 Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies The US company Celgene has obtained options to three cancer immunotherapy programs from the German biotech Immatics in a deal worth more than €1.35B ($1.5B). Immatics is to receive an upfront payment of €67.5M ($75M), along with up to €455M ($505M) in developmental milestones and royalties for each immunotherapy program. In each program, Immatics will […] August 28, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2018 Personalized Immunotherapy for Brain Cancer Succeeds in Clinical Trials A European trial has proved the feasibility and efficacy of treating cancer with a personalized immunotherapy tailored to each patient. The phase I/II trial, run across six European centers, tested a combination of two personalized vaccines in patients with glioblastoma, an aggressive form of brain cancer. The first vaccine was designed to immunize the patients […] December 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2018 Money, Money, Money! Europe’s Best-Funded Biotechs in 2018 Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where many of us re-examine our finances and budget for the year ahead. With money on the brain, we thought it would be a good time to do a roundup of Europe’s best-funded private biotechs. With over €400M raised to date, […] February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2017 Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both companies signed a billion-dollar partnership. Immatics, a company based in Tübingen specialized in cancer immunotherapy, has announced that its Series E round has reached $58M (€50M). Existing investors including dievini Hopp Biotech, Wellington Partners, and AT Impf took part in the fundraising, which […] October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2017 German Pharma Enters the Clinic with Solid Tumor Treatment A Phase I study will investigate the safety and tolerability of Immatics approach to treating solid tumors. Immatics is a German biopharma based in Tuebingen, which is a leader in the field of cancer immunotherapy. It has announced today the initiation of a Phase I trial that will test the safety and tolerability of its […] September 28, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 21 Aug 2017 German Biotech Starts Trials with a Personalized Cell Therapy for Multiple Cancers Immatics will start a first clinical trial to test IMA101, a personalized cell therapy with the potential to treat multiple types of solid tumors. Based in Tübingen, Germany, Immatics has announced today the start of its first clinical trial testing its cell therapy technology aimed at providing personalized treatments for multiple types of solid tumors. The […] August 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Infographics 13 Feb 2017 Infographic: What’s in Europe’s Immuno-oncology Pipeline? While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is […] February 13, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email